Design and analysis issues for economic analysis alongside clinical trials

Area of Science:

• Health Economics
• Clinical Trial Design
• Pharmacoeconomics

Background:

• Clinical trials offer efficient data collection for health economic evaluations.
• Fundamental differences exist between clinical and economic study objectives.
• Economic evaluations require specific data on health resource utilization and outcomes.

Purpose of the Study:

• To review the design and analysis considerations for trial-based cost-effectiveness studies.
• To highlight the unique requirements of economic evaluations compared to traditional clinical trials.
• To guide researchers in optimizing clinical trials for economic data collection.

Main Methods:

• Review of trial design principles for economic data collection.
• Discussion of analytical methods for cost-effectiveness analysis.
• Consideration of factors influencing trial suitability for economic evaluation.

Main Results:

• Randomized controlled trials (RCTs) are designed for safety/efficacy, not routine practice effectiveness.
• Cost-effectiveness analysis (CEA) requires collecting health resources over equal timeframes for each treatment.
• Trial comparators, follow-up duration, population, and effectiveness measures must align with economic goals.

Conclusions:

• Assessing trial suitability for economic data requires evaluating comparator treatments and protocol alignment with clinical practice.
• Sufficient trial follow-up is essential to capture all relevant costs and effects.
• Economic analyses benefit from broad patient populations and patient-centered effectiveness measures.
• Addressing missing/censored cost data, uncertainty in incremental cost-effectiveness ratios (ICERs), and subgroup heterogeneity are key analytical challenges.
• Multinational studies require careful consideration of differing practice patterns.